Clinical characteristics and analysis of drug treatment efficacy in hospitalized patients with sudden hearing loss due to enlarged vestibular aqueduct syndrome.
10.13201/j.issn.2096-7993.2025.03.009
- Author:
Hua WANG
1
;
Xiaonan WU
1
;
Jing GUAN
1
;
Jiao ZHANG
1
;
Dayong WANG
1
;
Qiuju WANG
1
Author Information
1. Department of Audiology and Vestibular Medicine，Senior Department of Otolaryngology Head and Neck Surgery，the Sixth Medical Center of Chinese PLA General Hospital，Beijing，100853，China.
- Publication Type:Journal Article
- Keywords:
curative effect;
large vestibular aqueduct syndrome;
medication;
sudden hearing loss
- MeSH:
Humans;
Male;
Retrospective Studies;
Hearing Loss, Sudden/etiology*;
Female;
Vestibular Aqueduct/pathology*;
Adult;
Child;
Adolescent;
Child, Preschool;
Young Adult;
Treatment Outcome
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2025;39(3):233-238
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical characteristics, audiological outcomes, and factors influencing the efficacy of pharmacological treatment in patients with sudden hearing loss associated with large vestibular aqueduct syndrome（LVAS）. Methods:A retrospective analysis was conducted on the clinical data of 77 bilateral LVAS patients（117 ears） hospitalized for sudden hearing loss from January 1, 2009, to December 31, 2023. The inclusion criteria required that patients to be diagnosed according to the Valvassori standard and had received standardized pharmacological treatment. Clinical features, audiological outcomes, and treatment efficacy were analyzed. Statistical methods were employed to identify factors associated with treatment outcomes. Results:The age of the enrolled patients ranged from 4 to 37 years. The age of onset for the initial hearing fluctuation varied between 0 and 24 years, with a mean age of 5.8 years. The male-to-female ratio was approximately balanced（37 males and 40 females）. The proportion of unilateral to bilateral sudden hearing loss was 1.0︰1.2, with unilateral right ear hearing loss being more frequently occurring（64.9%）. Triggering Factors: Triggers included no identifiable factors in 48.1% of cases, a history of head trauma（24.7%）, upper respiratory tract infections（11.7%）, onset following physical fatigue（11.7%）, and less frequently, noise exposure, alcohol consumption, or emotional stress（each 1.3%）. Clinical Symptoms: Hearing loss was the sole symptom in 35.1% of cases. Concurrent symptoms included vertigo in 44.2% and tinnitus in 46.8%. Patients with a disease duration of ≤14 days demonstrated a treatment efficacy rate of 75.0%. Among those who responded to treatment, 93.0% had profound or greater hearing loss prior to therapy, with an average improvement in hearing thresholds of 32 dB HL. In pretreatment, 68.9% of patients exhibited low-frequency air-bone gaps, increasing to 76.1% post-treatment. Additionally, 17.6% of treated ears demonstrated a ≥15 dB HL improvement in low-frequency bone conduction thresholds. In the non-responsive group, 7.3% of ears still showed some improvement in bone conduction thresholds. Statistically significant differences（P<0.05） were observed between the treatment-effective and non-effective groups concerning the age of initial hearing fluctuation, disease duration, and severity of hearing loss at onset. Conclusion:The efficacy of pharmacological treatment for sudden hearing loss in LVAS patients is influenced by the age at onset, duration of the disease, and severity of hearing impairment. Early diagnosis and timely intervention significantly enhance treatment efficacy, particularly in patients with a disease duration of ≤14 days and an initial sudden hearing loss. Patients with severe hearing loss, especially those with profound or greater impairment, exhibit greater sensitivity to treatment. Pharmacological interventions positively impact both air conduction and bone conduction thresholds, with the observed improvement in bone conduction thresholds warranting further investigation.
